Which rebate is based on achieving clinical or utilization targets?

• A. Drug Rebates
• B. Net Price
• C. Access Rebate
• D. Performance Rebate

Answer: (D)

A performance rebate is designed to be earned only when predefined outcomes are achieved. In value-based or performance-based contracting, the manufacturer promises a rebate to the payer if clinical targets (like improved disease control, specific biomarker improvements, or reduced hospitalizations) or utilization targets (such as appropriate use or reduced ER visits) are met. This ties the rebate directly to the value delivered by the therapy: when targets are reached, the payer receives a financial concession that lowers net cost; when targets aren’t met, the rebate may not be paid.

Drug rebates, by contrast, are discounts off the list price and aren’t inherently tied to meeting clinical or utilization targets. Net price is the price after all rebates and discounts, not a type of rebate itself. Access rebates relate more to coverage or formulary access rather than outcomes or utilization metrics. So the rebate linked to achieving clinical or utilization targets best fits the concept of a performance rebate.